Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

CytoDyn Inc CYDY

CytoDyn Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells. It has studied leronlimab in multiple therapeutic areas, including infectious disease, oncology, and autoimmune conditions. The Company has conducted clinical trials of leronlimab as a viral entry inhibitor for human immunodeficiency virus (HIV), believed to competitively bind to the N-terminus and second extracellular loop of the CCR5 receptor. For immunology, the CCR5 receptor is believed to be implicated in immune-mediated illnesses such as Metabolic dysfunction-associated steatohepatitis. It has a joint development agreement with a third-party generative artificial intelligence (AI) drug discovery and development company to develop one or more longer-acting molecules.


OTCQB:CYDY - Post by User

<< Previous
Bullboard Posts
Next >>
Post by My19sixyNineZon Mar 04, 2024 11:40pm
67 Views
Post# 35914981

Thank you Dr. J & Mgt, BOD & Advisors !!

Thank you Dr. J & Mgt, BOD & Advisors !!

Trying to give thanks @  Yazooo & keeps deleting. 

 

They've  tossed tha baby out with the bath water AND did a remodeling.

 

I could laundry list the good & then bad i pointed out --- also how bad i was bad mouthed. Both sides of my DD was correct.

 

Remember also was me who pointed out when it was said the 2 Vs 4 dosing was questioned. It caused all those comments / letters / videos, from doctors, etc., about the FDA.

 

Couple months later FDA broke tradition & issued that un-signed letter.

 

My point is, the voice of that webinar comments was ---- Dr. J.
 

His honesty on the dosing to the shareholders, earned my respect from there frwd.

Phenominal hearing him now say --- Cytodyn finally, has a working, collaborating relationship with the FDA & how grateful he is for their in-put, for succeeding. Awesome.

 

From Interim CEO webinar, he is hitting the milestones stated. CEO position to expand all things mentioned.

 

So good to see this cleaned-up & safe for trials, in 24 months. Staggering time actually.

 

The world needs Leronlimab & regardless of indication direction, i absolutely trust Dr. J 100%!!

GLTA!!

<< Previous
Bullboard Posts
Next >>